Company intelligence / Profile preview

AxxessBio

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

AxxessBio is an active Singapore-based specialty pharmaceutical and medical device distributor. The company partners with global biopharma firms to introduce innovative therapies in Asia, focusing on rare diseases and specialty therapeutics. In 2023, it secured exclusive distribution rights for Translarna™ (ataluren) for Duchenne muscular dystrophy and Upstaza™ (eladocagene exuparvovec) for AADC deficiency in several Southeast Asian countries.

Therapeutic areas: Rare Diseases
Modalities: Small moleculeGene therapy
Industry: Biotech

Drug pipeline

4 assets

Translarna

Commercial

Indications: Duchenne muscular dystrophy

3 more assets in the full pipeline.

Request access →

Partnerships

PTC Therapeutics International LimitedOther global pharma/biotech companies not specifically named

Beyond the preview

Go deeper on AxxessBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AxxessBio.

Explore the full profile